|Bid||0.00 x 800|
|Ask||0.00 x 800|
|Day's Range||14.27 - 15.97|
|52 Week Range||13.25 - 15.97|
|Beta (3Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Arix Bioscience plc (ARIX.L) ("Arix"), a global healthcare and life science company supporting medical innovation notes one of its portfolio companies, Harpoon Therapeutics, Inc. (HARP) ("Harpoon") a clinical-stage immunotherapy company developing a novel class of T cell engagers, has reported the closing of its initial public offering of 5,400,000 shares of common stock at a public offering price of $14.00 per share for gross proceeds of $75.6 million, before deducting underwriting discounts and commissions and offering expenses payable by Harpoon.
The IPO market is expected to show another uptick in volume this week as six initial public offerings are set to price and raise $882.6 million in proceeds. It follows three IPOs last week.
ShockWave has raised about $150 million in funding from investors who include Venrock, T. Rowe Price, Sectoral Asset Management, Sofinnova Capital and Fidelity.
For a more comprehensive IPO calendar, check out the offering in Benzinga Cloud . IPO dates below are expected but not confirmed. Alector, Inc. (ALEC) will issue 9.25 million shares between $18 and $20 ...